Oral small molecule - Pan-Biome Pharmaceutical
Latest Information Update: 28 Mar 2025
At a glance
- Originator Pan-Biome Pharmaceuticals
- Class Anti-inflammatories; Antihyperglycaemics; Obesity therapies; Small molecules
- Mechanism of Action Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Inflammatory bowel diseases; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Inflammation in Canada (PO)
- 28 Mar 2025 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Canada (PO)
- 28 Mar 2025 No recent reports of development identified for preclinical development in Obesity in Canada (PO)